[{"id":"5f261933-8667-498d-b336-e29f4bb26d7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00125359","created_at":"2021-01-18T00:25:25.794Z","updated_at":"2024-07-02T16:37:04.169Z","phase":"Phase 2","brief_title":"Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer","source_id_and_acronym":"NCT00125359","lead_sponsor":"Konstantin Dragnev","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Targretin oral (bexarotene oral)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 08/01/2005","start_date":" 08/01/2005","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2019-01-08"},{"id":"ce573b71-cfca-4025-b0e8-2d3f560e4f32","acronym":"","url":"https://clinicaltrials.gov/study/NCT00125372","created_at":"2021-01-18T00:25:26.483Z","updated_at":"2024-07-02T16:37:04.177Z","phase":"","brief_title":"Study of Tarceva and Targretin in Stage I-II Lung Cancer","source_id_and_acronym":"NCT00125372","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" EGFR • CCND1","pipe":" | ","alterations":" EGFR mutation • EGFR expression • CCND1 expression","tags":["EGFR • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR expression • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Targretin oral (bexarotene oral)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2005","start_date":" 12/01/2005","primary_txt":" Primary completion: 08/01/2010","primary_completion_date":" 08/01/2010","study_txt":" Completion: 08/01/2010","study_completion_date":" 08/01/2010","last_update_posted":"2019-01-08"}]